Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Endocrine 2

Conditions

Carcinoma, Hepatocellular 17Differentiated Thyroid Cancer 2Colorectal Neoplasms 2Cholangiocarcinoma 2Stomach Neoplasms 1Solid Tumor 1Recurrence 1Pancreatic Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced Thyroid Gland Carcinoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Hepatocellular Carcinoma with PVTT 1Esophageal Neoplasms 1Digestive System Neoplasms 1Diabetes Mellitus 1Cirrhosis, Familial, with Pulmonary Hypertension 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Biliary Tract Carcinoma 1Biliary Tract Adenocarcinoma 1Biliary Malignant Tumors 1Advanced Solid Tumor 1

Interventions

Thyrotropin Alfa 4donafenib 2Injections 2vandetanib 1surufatinib 1pembrolizumab 1lenvatinib 1apatinib 1anlotinib 1Sorafenib 1Iodine-131 1Everolimus 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Differentiated Thyroid Cancer × donafenib × Clear all
NCT03602495 2021-12-13

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 3 Terminated
204 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT02870569 2019-03-01

Phase 2 Trial of Donafenib in 131I-Refractory Differentiated Thyroid Cancer

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Completed
48 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡